Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders, initially scheduled for August 15, 2024, and reconvened on August 19, 2024. The meeting was adjourned due to the lack of a quorum as proxies submitted represented approximately 49.7% of the outstanding shares, falling short of the majority required. The Special Meeting is rescheduled to reconvene on August 20, 2024, at 9:00 a.m. Central Time, to be held virtually. The company is soliciting additional votes regarding the proposal outlined in the definitive proxy statement filed with the SEC on July 30, 2024. Stockholders who have not voted are urged to do so as soon as possible. Exicure is currently exploring strategic alternatives to maximize stockholder value following its restructuring and suspension of clinical and development activities.

Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders, initially scheduled for August 15, 2024, and reconvened on August 19, 2024. The meeting was adjourned due to the lack of a quorum as proxies submitted represented approximately 49.7% of the outstanding shares, falling short of the majority required. The Special Meeting is rescheduled to reconvene on August 20, 2024, at 9:00 a.m. Central Time, to be held virtually. The company is soliciting additional votes regarding the proposal outlined in the definitive proxy statement filed with the SEC on July 30, 2024. Stockholders who have not voted are urged to do so as soon as possible. Exicure is currently exploring strategic alternatives to maximize stockholder value following its restructuring and suspension of clinical and development activities.